Search

CN-122028805-A - Composition comprising human milk oligosaccharides for use in individuals to support brain development and/or social mood development

CN122028805ACN 122028805 ACN122028805 ACN 122028805ACN-122028805-A

Abstract

The present invention provides a fucosylated Human Milk Oligosaccharide (HMO) for use in improving brain development and/or social emotional development of an individual, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child or a child.

Inventors

  • J. HAUSER
  • D. Burkich
  • T. M. Samuel
  • N. Sprenger
  • CAO RUIYIN
  • YIN WEIYAN
  • LI TENGFEI
  • ZHU ZILIANG
  • ZHU HONGTU
  • LIN WEILI

Assignees

  • 雀巢产品有限公司

Dates

Publication Date
20260512
Application Date
20240820
Priority Date
20230829

Claims (19)

  1. 1. A fucosylated Human Milk Oligosaccharide (HMO) for use in improving brain development and/or social mood development of an individual, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child, or a child.
  2. 2. A nutritional composition comprising a fucosylated HMO for use in improving brain development and/or social mood development in an individual, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child, or a child.
  3. 3. The fucosylated HMO for the use according to claim 1 or the nutritional composition for the use according to claim 2, wherein the infant is at least 5 months of age.
  4. 4. The fucosylated HMO for the use according to claim 1 or claim 3 or the nutritional composition for the use according to claim 2 or claim 3, wherein the improvement in brain development and/or social mood development of the individual comprises or consists of an improvement in development of a brain network associated with social mood function.
  5. 5. The fucosylated HMO for use according to any of claims 1,3 or 4 or the nutritional composition for use according to any of claims 2 to 4, wherein improving brain development and/or social mood development of the individual comprises or consists of promoting a Default Mode Network (DMN).
  6. 6. Nutritional composition for the use according to any one of claims 2 to 5, wherein the nutritional composition is an infant formula, a range of infant formulas, a range of larger or range of two infant formulas, a baby food, an infant cereal composition, a growing-up milk, a fortifier or a supplement.
  7. 7. Nutritional composition for the use according to any one of claims 2 to 6, wherein 3-FL is present in a total amount of 50mg/L to 2000mg/L of the nutritional composition or 38mg/100g to 1540mg/100g of the nutritional composition.
  8. 8. Use of a fucosylated HMO for improving brain development and/or social mood development in an individual, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child or a child, preferably wherein the infant is at least 5 months of age.
  9. 9. Use of a nutritional composition comprising a fucosylated HMO for improving brain development and/or social mood development in an individual, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child or a child, preferably wherein the infant is at least 5 months of age.
  10. 10. The use of claim 8 or claim 9, wherein the improvement in brain development and/or social emotional development of the individual comprises or consists of an improvement in development of a brain network associated with social emotional function, preferably wherein the improvement in brain development and/or social emotional development of the individual comprises or consists of promoting a Default Mode Network (DMN).
  11. 11. Use of a fucosylated HMO for promoting a Default Mode Network (DMN) in an individual, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child or a child, preferably wherein the infant is at least 5 months of age.
  12. 12. Use of a nutritional composition comprising a fucosylated HMO for promoting a Default Mode Network (DMN) in an individual, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child or a child, preferably wherein the infant is at least 5 months of age.
  13. 13. The use according to any one of claims 9, 10 or 12, wherein the nutritional composition is an infant formula, a range of infant formulas, a range of larger or range of binary infant formulas, baby food, an infant cereal composition, a growing-up milk, a fortifier or a supplement.
  14. 14. A method of improving brain development and/or social mood development in an individual, the method comprising administering to the individual a fucosylated HMO, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child, or a child, preferably wherein the infant is at least 5 months of age.
  15. 15. A method of improving brain development and/or social mood development in an individual, the method comprising administering to the individual a nutritional composition comprising a fucosylated HMO, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child, or a child, preferably wherein the infant is at least 5 months of age.
  16. 16. A method of promoting a Default Mode Network (DMN) in an individual, the method comprising administering to the individual a fucosylated HMO, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child, or a child, preferably wherein the infant is at least 5 months of age.
  17. 17. A method of promoting a Default Mode Network (DMN) in an individual, the method comprising administering to the individual a nutritional composition comprising a fucosylated HMO, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child, or a child, preferably wherein the infant is at least 5 months of age.
  18. 18. The method of claim 14 or claim 15, wherein the improvement in brain development and/or social emotional development of the individual comprises or consists of an improvement in development of a brain network associated with social emotional function, preferably wherein improving brain development and/or social emotional development of the individual comprises or consists of promoting a Default Mode Network (DMN).
  19. 19. The method of any one of claims 15, 17 or 18, wherein the nutritional composition is an infant formula, a range of infant formulas, a range of larger or second infant formulas, a baby food, an infant cereal composition, a growing-up milk, a fortifier, or a supplement.

Description

Composition comprising human milk oligosaccharides for use in individuals to support brain development and/or social mood development Technical Field The present invention relates to a nutritional composition comprising at least one fucosylated human milk oligosaccharide for use in an individual to support brain development and/or social mood development. In particular, the nutritional composition comprises 3-fucosyllactose (3-FL). Brain development and/or social emotional development includes development of a brain network that supports social emotional functions, such as a Default Mode Network (DMN). Background In recent years, there has been a great deal of attention to identify potential relationships between Human Milk Oligosaccharides (HMOs) and early brain development. Preliminary evidence based on animal studies has indicated that HMOs can play a significant role in central nervous system development. For example, the use of prolonged oral administration of 2' -FL to rodents, vazquez et al demonstrated that the treated animals exhibited significantly better learning and working memory functions (Vazquez et al 2015, journal of nutritional biochemistry, 26 (5): 455-465). However, there is little data on the potential impact of other HMOs on infancy and early childhood brain function development. To our knowledge, the present study was the first study to determine any HMO, let alone fucosylated HMO 3-fucosyllactose (3-FL), specifically the association of social emotional development. There is a need for nutritional compositions that can deliver such health benefits. There is a need to deliver such health benefits to an individual in a manner that does not induce side effects and/or in a manner that is not only easy to deliver (e.g., as a nutritional composition or during a meal) but also that is widely recognized by parents or health care providers. There is also a need to deliver such benefits in a way that keeps such delivery costs reasonable and affordable to most people. Disclosure of Invention The inventors have surprisingly found that fucosylated HMO 3-fucosyllactose (3-FL) is significantly associated with brain and social emotional development of infants and children, and in particular, development of social emotional brain networks such as Default Mode Networks (DMNs). While other fucosylated HMOs, such as a-tetraose, are not. Thus, in a first aspect, the present invention provides a fucosylated Human Milk Oligosaccharide (HMO) for use in improving brain development and/or social mood development of an individual, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child or a child. In a further aspect, the present invention provides a nutritional composition comprising a fucosylated Human Milk Oligosaccharide (HMO) for use in improving brain development and/or social mood development of an individual, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child, or a child. In a further aspect, the invention provides a method of improving brain development and/or social mood development in an individual, the method comprising administering to the individual a fucosylated HMO, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child, or a child. In a further aspect, the invention provides a method of improving brain development and/or social mood development in an individual, the method comprising administering to the individual a nutritional composition comprising a fucosylated HMO, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child, or a child. In a further aspect, the present invention provides a fucosylated HMO for use in improving brain development and/or social emotional development of an individual, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child, or a child. In a further aspect, the invention provides a nutritional composition comprising a fucosylated HMO for use in improving brain development and/or social emotional development of an individual, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child, or a child. In some embodiments, the improvement in brain development and/or social emotional development of the individual includes or consists of an improvement in development of a brain network associated with social emotional function. In some embodiments, improving brain development and/or social emotional development of the individual includes or consists of promoting a Default Mode Network (DMN). Thus, in a further aspect, the invention provides the use of a fucosylated HMO for promoting a Default Mode Network (DMN) in an individual, wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the individual is an infant, a young child or a child